Skip to main content

Advertisement

Table 2 Distribution of the studies according to each possible methodological choice

From: Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis

Category Nalmefene (n = 9) Naltrexone (n = 51)
Medical condition
 AD only 6 (66.7%) 33 (64.7%)
 AUDs 3 (33.3%) 18 (35.3%)
Abstinence
 < 5 days 9 (100%) 34 (66.7%)
 ≥ 5 days 0 (0.0%) 17 (33.3%)
Gender
 Mixed 9 (100%) 39 (76.5%)
 Males or females only 0 (0.0%) 12 (23.5%)
Systematic somatic comorbidity
 No 9 (100%) 48 (94.1%)
 Yes 0 (0.0%) 3 (5.9%)
Systematic psychiatric comorbidity
 No 9 (100%) 39 (76.4%)
 Yes 0 (0.0%) 12 (23.5%)
Psychological support
 No 1 (11.1%) 4 (7.8%)
 Yes 8 (88.9%) 47 (92.2%)
Treatment and dose
 Approved dose and route of administration
  No 6 (66.7%) 14 (27.5%)
  Yes 3 (33.3%) 37 (72.5%)
 Maximum dose tested
  No 8 (88.9%) 50 (98.0%)
  Yes 1 (11.1%) 1 (2.0%)
Treatment duration
 ≥ 12 weeks 9 (100%) 41 (80.4%)
 < 12 weeks 0 (0.0%) 10 (19.6%)
Outcome reported
 Quantity of alcohol consumed
  No 0 (0.0%) 21 (41.2%)
  Yes 9 (100%) 30 (58.8%)
 Frequency of drinking
  No 2 (22.2%) 16 (31.4%)
  Yes 7 (77.8%) 35 (68.6%)
 Abstinence
  No 0 (0.0%) 18 (35.3%)
  Yes 9 (100%) 33 (64.7%)
Publication
 Published 7 (77.8%) 48 (94.1%)
 Unpublished 2 (22.2%) 3 (5.9%)
Risk of bias
 High risk of selective outcome reporting 2 (22.2%) 5 (9.8%)
 Unclear or low risk of selective outcome reporting 7 (77.8%) 46 (90.2%)
  1. Numbers are presented with their corresponding percentage
  2. AD alcohol dependence, AUD alcohol use disorder